← All trials
NCT05242445
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 19, 2022
- Primary completion
- Apr 1, 2024
- Completion date
- Apr 15, 2024
- First posted
- Feb 16, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 40
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Johnson and JohnsonStudy director
- Johnson and JohnsonOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.